PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

By Choo Edna   Ng Chee   Berry Leanne   Belvin Marcia   Lewin-Koh Nicholas   Merchant Mark   Salphati Laurent  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 133-143

Springer Publishing Company

Access to resources Recommend Favorite

Current Development of Pd(II) Complexes as Potential Antitumor Agents

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 3, 2009-03 ,pp. : 356-368

Bentham Science Publishers

Access to resources Recommend Favorite

Proteomics Benefits Drug Discovery and Development

By  

The Genesis Report - Rx, Vol. 9, Iss. 4, 2000-06 ,pp. : 47-48

Adis International

Access to resources Recommend Favorite

Development and regulation of monoclonal antibody products: Challenges and opportunities

By Weinberg Wendy   Frazier-Jessen Michelle   Wu Wen   Weir Andrea   Hartsough Melanie   Keegan Patricia   Fuchs Chana  

Cancer and Metastasis Reviews, Vol. 24, Iss. 4, 2005-12 ,pp. : 569-584

Springer Publishing Company

Access to resources Recommend Favorite

Challenges in the development of magnetic particles for therapeutic applications

By Barry Stephen  

International Journal of Hyperthermia, Vol. 24, Iss. 6, 2008-01 ,pp. : 451-466

Informa Healthcare

Access to resources Recommend Favorite